News and Announcements
TYMLEZ has achieved partner status in the Google Cloud Technology program
- Published February 05, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
TYMLEZ Group Limited (“TYMLEZ” or the “Company”) is pleased advise that it has officially achieved partner status in the Google Cloud Technology Partner Program.
This allows the Company to list the TYMLEZ Solution Blockchain Platform (TBSP) on the Google Cloud Platform Marketplace to promote and sell TYMLEZ solutions to customers.
The Company will also receive additional training material for our developers and receive credits from Google to use the Google Cloud Platform for development and testing environments, customer demonstrations, and customer “proof of concept” opportunities.
Commenting on the Google Cloud Technology partnership, CEO of TYMLEZ, Michael Reh, said: “we are very pleased to be on the Google Cloud Technology Partner Program, this is a great endorsement of our platform and an excellent distribution platform for accelerated and scalable sales growth. We look forward to updating investors on this exciting development for the Company
About TYMLEZ
TYMLEZ develops a platform that enables the enterprise to develop applications utilising BLOCKCHAIN technology. The platform is hyper-scalable and enterprise grade. TYMLEZ is one of the rare companies in the blockchain space (61.5% CAGR1 to 2021) that is generating revenues. TYMLEZ is starting to scale its Blockchain-as-a-Service (BaaS) revenue base. Major partners and customers include Fujitsu, Intel, Grant Thornton, Magic and KPN.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
